

# Structural difference analysis of adult's intestinal flora basing on the 16S rDNA gene sequencing technology

H.-J. YU<sup>1</sup>, C. JING<sup>1</sup>, N. XIAO<sup>2</sup>, X.-M. ZANG<sup>1</sup>, C.-Y. ZHANG<sup>3</sup>, X. ZHANG<sup>1</sup>, Y.-N. QU<sup>1</sup>, Y. LI<sup>1</sup>, Q.-W. TAN<sup>1</sup>

<sup>1</sup>College of Acupuncture and Massage, Shandong University of Traditional Chinese Medicine, Jinan, China

<sup>2</sup>State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China

<sup>3</sup>Department of Treatment and Prevention Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China

**Abstract. – OBJECTIVE:** Through 16S rDNA technology, we aimed at separating adults aging 20-50 years old into a few groups and processing the high-throughput sequencing analysis, in order to explore the features and differences of intestinal flora in each age group in a microcosmic perspective.

**PATIENTS AND METHODS:** 120 stool specimens were collected strictly in accordance with acceptance criteria and exclusion criteria. 49 subjects aging 20-29 years old (Group AGE1), 51 subjects aging 30-39 years old (Group AGE2), and 20 subjects aging 40-49 years old (Group AGE3) were divided into 3 groups. Bacteria DNA from fresh stool specimens of 3 groups were abstracted. Illumina MiSeq high-throughput sequencing platform was applied to process 16S rDNA sequencing in Area 338F\_806R for intestinal flora detection. I-Sanger Bio-cloud platform was applied for the analysis of intestinal flora structure changes in phylum level and genus level.

**RESULTS:** Among the age of 20-50, with older age, the abundance of intestinal flora decreased among healthy adults more than 40 years old. In addition, the diversity and sample dispersion of intestinal flora is significantly different from people among 20-40 years old. The decrease ratio of *Firmicutes/Bacteroidetes* indicated that as the age grows, glucose tolerance might decrease. Comparing with people among 20-40 years old, the amount of *Bifidobacterium* and *Eubacterium* in people over 40 years old have significantly decreased. The decrease of *Bifidobacterium* and *Eubacterium* may increase the risks of cognitive impairment and lower the anti-inflammation and anti-cancer efficacy in human body, respectively. *Subdoligranulum* relates to poor metabolism and chronic in-

flammation and it happens more in people aged over 40 than young people who are among 20-40 years old.

**CONCLUSIONS:** There are differences in the intestinal flora of healthy adults aged 20-50. Effective intervention of the intestinal flora may play a role in delaying aging and preventing diseases.

*Key Words:*

Intestinal flora, Bacteria DNA, Adult, 16S rDNA.

## Introduction

Intestinal microorganism is an active participant of host physiology and relates to the changes of gastrointestinal microorganism, as well as human and animal's disease, including cystic fibrosis<sup>1</sup>, inflammatory bowel disease (irritable bowel syndrome, Crohn's disease and colon cancer)<sup>2-4</sup>, nervous system disease (Parkinson's disease, Alzheimer's disease, and multiple sclerosis)<sup>5-7</sup>, metabolic disease (obesity and diabetes)<sup>8,9</sup> and disease related to muscle and skeleton (weakness, osteoporosis, rheumatoid arthritis and gout)<sup>10-13</sup>.

Age is an important factor that affects the structure and constitution of intestinal microorganism. Human intestinal flora is different in species abundance according to different ages<sup>14-16</sup>. The age division is general and most of the studies concentrate on the comparison of aged 20-50 and people over 60<sup>17-22</sup>. The structure and constitution of adult's intestinal flora in different ages still needs further detailed research. Epidemiol-

ogy research indicated that people over 50 years old have significantly increased percentage to have type 2 diabetes, hypertension, brain stroke, non-alcoholic fatty liver, and obesity<sup>23-25</sup>. To study the structure and constitution features of adults among 20-50 years old, we can make targeted adjustment to intestine, which can play an important role in anti-aging and disease prevention, as well as match the traditional Chinese medicine's idea of "cure before illness". 16S rDNA, existing in all organism, is the most useful and commonly used molecular clock in systematic classification of bacteria. With its appropriate size, it can reflect the differences among bacteria and can gain their sequence by sequencing technology. So, it is widely accepted by bacteriologists and taxonomists.

Through the 16S rDNA technology, the study separated adults aging 20-50 years old into a few groups and processed the high-throughput sequencing analysis, and explored the features and differences of intestinal flora in each age group in a microcosmic perspective.

## Patients and Methods

### *Research Object and Grouping*

This study was approved by the Ethics Committee of Affiliated Hospital of Shandong University of Traditional Chinese Medicine. Signed written informed consents were obtained from all participants before the study. The study objects are from Curing Before Illness Center of the Affiliated Hospital of the Shandong University of Traditional Chinese Medicine. Ethical batch number is 2018-033-KY. Questionnaire investigation method was adopted to collect the age, gender, living habit information (including smoking, drinking and diet) and human body measurement information (including height, weight, blood pressure, physical quality index, waist circumference, hip circumference, and body fat rate). 120 stool specimens were collected strictly in accordance with the acceptance criteria and exclusion criteria. 49 subjects (25 male and 24 female) aging 20-29 years old (Group AGE1), 51 subjects (29 male and 22 female) aging 30-39 years old (Group AGE2) and 20 subjects (6 male and 14 female) aging 40-49 years old (Group AGE3) were divided into 3 groups. Bacteria DNA from fresh stool specimens of 3 groups were abstracted. Inclusion criteria are shown as follows: (1) age among 20-50 years old; (2) living in Jinan more than 1 year

and no antibiotics were taken within 1 month; (3) no serious illness and who signed the Informed Consent Form. Exclusion criteria are shown as follows: (1) take each kind of medicine or accept other therapies; having other serious diseases; (2) women in pregnancy and lactation period.

### *Stool Specimens Collection*

Enrolled subjects adopted their stool specimens in outpatient department. Subjects with special situations, such as diarrhea and female menstruation should postpone to adopt the sample. After emptying the bladder, the subject adopted fresh and natural discharge around 2 g and put it in a 2 mL test tube (Biologix, Jinan, China) immediately. Specimens were kept under liquid nitrogen condition.

### *Abstraction of Stool's DNA and 16S rDNA Sequencing Analysis*

Detection of the specimens were completed by Shanghai Majorbio Technology Co., Ltd. (Shanghai, China). Database was created for qualified DNA specimens. PCR amplification was processed according to 338F\_806R region. Passing the quantified detection, we built up Miseq library and performed sequencing. PE (paired-end) acronym readings from Miseq sequencing were jointed together according to overlap relationship. Operational Taxonomic Unit (OTU) cluster analysis and taxonomic analysis were processed in all sequencing. We calculated specimens community structure mainly in phylum level and genus level.

### *Bioinformatics Analysis*

PE reads from Miseq sequencing were jointed together according to overlap relationship. According to different similarity level, processed OTU cluster analysis for all sequencing. We adopted a RDP classifier Bayesian algorithm to conduct taxonomic analysis and calculated each sample's community composition on each classification level. Based on OTU and its cluster analysis results as well as the taxonomic information, in-depth analysis of community structure in each classification level, such as PLS-DA, Partial Least Squares Discriminant Analysis, cluster composition analysis and Wilcoxon rank sum test can be conducted.

### *Statistical Analysis*

We adopted Statistical Product and Service Solutions (SPSS) 25.0 software (IBM Corp., Armonk, NY, USA) to process statistical analysis.

**Table I.** General Comparison Among Three Groups (mean ± SD).

General Situation	AGE1 (n = 49)	AGE2 (n = 51)	AGE3 (n = 20)	p-value
BMI (kg/m <sup>2</sup> )	24.8078 ± 0.7155	25.8743 ± 0.68981	25.545 ± 0.95698	p = 0.543 > 0.05
Waist-to-Hip Ratio (WHR)	0.8833 ± 0.01022	0.9106 ± 0.01039	0.8945 ± 0.01778	p = 0.187 > 0.05

The measurement data used the *t*-test of independent samples. The data were expressed as mean ± standard deviation, and *p*<0.05 indicated that the difference was statistically significant.


## Results

### General Comparison

Body Mass Index (BMI) and Waist-to-Hip Ratio (WHR) among the three groups showed no significant difference but could be comparable. *p*>0.05 (Table I)

### Diversity Index Analysis

Diversity index means sobs (the species number in actual observation). When the curve tends to be flat, it means that the sequencing quantity is abundant. More sequencing quantity (abscissa) does not contribute a lot to the numbers of OTU (ordinate). It indicates that current sequencing quantity can reflect the species diversity of the specimens (Figure 1).




**Figure 1.** AGE1, AGE2, AGE3 species rarefaction curve. Each color represents one group. The abscissa is the number of sampling sequences and ordinate is the OTU number of specimens. Different color indicated different specimens.

### Venn Diagram of OUT Distribution Differences Among Bacterial Groups at Different Ages


OUT number of Group AGE1 was 891, Group AGE2 was 919, and Group AGE3 853. The OUT number of Group AGE2 was more than Group AGE1 and Group AGE3 (Figure 2).

### Alpha Adversity Analysis of Bacteria Community in Three Groups

Alpha diversity of the three groups was calculated based on the OTU species and abundant in the specimens (Figure 3). The figure revealed the significant difference of specimens between the two selected groups. Two groups with significant differences were marked ( $0.01 < p \leq 0.05$  marked



**Figure 2.** Three Groups' OUT Number. Each color represents one group. The crossing part is the shared OTU with the adjacent group. Each number represents the independent or shared OTU number.



**Figure 3.** Bacteria diversity analysis among three specimens. This figure shows the significant differences between the three groups of samples selected. The test method is student's t-test, and the two groups with significant differences are marked. ( $*0.01 < p \leq 0.05$ ). The abscissa is the group's name while the ordinate is the index average of each group.

\*) Significant differences in bacteria diversity existed between Group AGE1 and Group AGE3, as well as between Group AGE2 and Group AGE3. No significant difference of bacteria di-


versity existed between Group AGE1 and Group AGE2. The result indicated that as the age grows, the bacteria diversity gradually increased.

### Partial Least Squares-Discriminant Analysis (PLS-DA Analysis)

Figure 4 indicated that according to PLS-DA analysis, three groups could be separated and clustered into groups. It revealed that intestinal flora in adults of different ages had significantly differences in OUT level. In addition, the dispersion degree of the specimen point distribution in the PLS-DA analysis can also be reflected that in the OTU level, the dispersion degree of the specimen point distribution in Group AGE1 and Group AGE2 was less than Group AGE3. The intestinal flora Group AGE1 and Group AGE2 had small differences. The difference of intestinal flora dispersion degree in Group AGE1 and Group AGE3, as well as Group AGE2 and Group AGE3 was big.

### Community Composition of Three Groups in Phylum Level and Kruskal-Wallis Test

The dominant bacteria of intestinal flora in the three groups were *Firmicutes*, *Bacteroidetes*, *Proteobacteria* and *Actinobacteria*. The abundance in the genus level was different. The ratio of *Bac-*



**Figure 4.** According to PLS-DA analysis, three groups could be separated significantly and clustered into groups. It revealed that intestinal flora in adults of different ages had significantly differences in OUT level.

**Table II.** Analysis of the proportion of three specimens in phylum level.

Group	Firmicutes	Bacteroidetes	Proteobacteria	Actinomycota	Bacteroidetes/Firmicutes
AGE1	72.67%	8.95%	9.57%	7.70%	0.123159
AGE2	77.18%	7.52%	6.80%	7.97%	0.097434
AGE3	80.54%	7.15%	6.42%	4.23%	0.088775

*teroidetes/Firmicutes* (B/F) in Group AGE1 was the highest, and Group AGE2 was the second and Group AGE3 the third. (Table II and Figure 5).

From Kruskal-Wallis Test (Figure 6), *Firmicutes* and *Actinobacteria* were the bacteria in phylum level that had significant difference in the intestinal floral of Group AGE1, Group AGE2, and Group AGE3 ( $p < 0.05$ ).

**Community Composition of Three Groups in Genus Level and Kruskal-Wallis Test**


The dominant bacteria of intestinal flora in the three groups were different. In Group AGE1, the first five were *Faecalibacterium*, *Blautia*, *Subdoligranulum*, *Eubacterium* and *Bifidobacterium*. The first five in Group AGE2 were *Faecalibacte-*

*rium*, *Eubacterium*, *Blautia*, *Bifidobacterium* and *Eubacterium*. The first five dominant bacteria were *Blautia*, *Subdoligranulum*, *Faecalibacterium*, *Eubacterium* and *Dialister*. Different bacteria has different relative abundance (Table III and Figure 7).


It was indicated by Kruskal-Wallis Test (Figure 8) that *Bifidobacterium*, *Escherichia-shigella*, *Eubacterium* and *Subdoligranulum* were the bacteria that had significant differences in genus level.

**Discussion**

Adult human intestines are colonized by large and complex microbiota, which have each vital



**Figure 5.** Column diagram of relative abundance of three groups of phylum level. The ordinate is the sample name, and the abscissa is the proportion of the species in the sample. The pillars of different colors represent different species, and the length of the pillars represents the proportion of the species.



**Figure 6.** Kruskal-Wallis Test of three groups in phylum level. The ordinate is the group's name in phylum level. The corresponding length of the column is the average relative abundance of that species in each specimen group. Different colors indicated different grouping. The rightmost side was  $p$  value. \*  $0.01 < p \leq 0.05$ , \*\*  $0.001 < p \leq 0.01$ , \*\*\*  $p \leq 0.001$ .

**Table III.** Analysis of the proportion of three specimens in genus level.


Group	<i>Faecalibacterium</i>	<i>Blautia</i>	<i>Subdoligranulum</i>	<i>Eubacterium</i>	<i>Bifidobacterium</i>
AGE1	12.227%	8.24%	6.85%	5.84%	5.47%
AGE2	12.18%	7.43%	5.25%	7.95%	5.86%
AGE3	10.29%	10.52%	10.44%	3.97%	1.87%

effects in the host system<sup>26-30</sup>. The host's genetic heritage, healthy condition, age, gender, diet habit, living environment, and social background all have co-influence in the colonization ability of intestinal flora and diversity of its composition<sup>31-34</sup>.


The subjects of the study were health adults with appropriate gender percentage and disperse in the same place of residence. It focused on how age affects intestinal flora. From the study result, it is indicated that as the adults' age increased, the abundance of intestinal flora decreased and the diversity index among each groups had significant difference. The PLS-DA analysis result also presented that the dispersion degree of the specimen point distribution was higher in Group AGE3 (40-49 years old) than Group AGE1 and Group AGE2 and it had significant difference. This is consistent with the literature<sup>35</sup>. The diversity of intestinal flora and relative abundance change as age increases. The diversity of elder's intestinal flora is higher than adults. Mueller et al<sup>36</sup> concluded that the structure and features of

the intestinal flora relate to age. According to the classification criteria of the World Health Organization (WHO), the subjects from Group AGE3 are not old people, but the changes of the abundance and diversity of intestinal flora were significant and it even tended to the changes of the old.

From the community composition in phylum level of three groups and Kruskal-Wallis test, we found that the *Firmicutes* and *Actinobacteria* had significant differences in three groups. *Firmicutes* and *Bacteroidetes* were the dominant bacteria<sup>37</sup> that had the most intestinal flora. That is the reason why the ratio of *Firmicutes* and *Actinobacteria* (F/B) can reflect the changes of the bacteria community in certain degree. Some research results revealed that the higher



**Figure 7.** Column diagram of relative abundance of three groups of genus level. The abscissa is the sample name, and the ordinate is the proportion of the species in the sample. The pillars of different colors represent different species, and the length of the pillars represents the proportion of the species.



**Figure 8.** Kruskal-Wallis Test of three groups in genus level. The ordinate is the group's name in genus level. The corresponding length of the column is the average relative abundance of that species in each specimen group. Different colors indicated different grouping. The rightmost side was *p*-value. \* 0.01 < *p* ≤ 0.05, \*\* 0.001 < *p* ≤ 0.01, \*\*\* *p* ≤ 0.001.

glucose intolerance, the less ratio of F/B. From our research result, it indicated that it is tended to have more *Firmicutes* and less *Actinobacteria* as the age increases. The change regularity of F/B ratio is in accordance with it. Among the three groups of healthy subjects, the ratio of F/B increased as the age increased. It indicated that as the age grows, the glucose tolerance may decrease and diabetes may process in some degree. The research conclusion about *Firmicutes* and *Actinobacteria* in the elder people's intestinal flora from other countries were different<sup>19,39-42</sup>. The clostridium cluster XIVA in *Firmicutes* of German increased while Italians, Finns, and Japanese decreased. The German and Finns's *Actinobacteria* increased while the Italians and North Europeans decreased. Regional, living habits, and a few factors may influence the intestinal flora. *Actinobacteria*, a vital source of natural medicine, can produce rich bioactive substance. Its metabolic substances have the features, such as antibacterial, antitumor and antiviral activities. The result in the study also indicated that *Actinobacteria* in Group AGE3 decreased significantly with less antibacterial, antitumor, and antiviral activities. This reflected the effect of age to intestinal flora.

From the community composition in phylum level of three groups and Kruskal-Wallis test, we found that the *Bifidobacterium*, *Escherichia-shigella*, *Eubacterium* and *Subdoligranulum* were the bacteria that had significant differences in genus level. Some researches revealed that *Bifidobacterium* relates closely to human health. To keep *Bifidobacterium* stable or increased is an important sign to stay healthy. Some researchers<sup>43</sup> found that increased *Bifidobacterium* can alleviate the cognitive impairment among Alzheimer's patients. *Escherichia-shigella* is a compound known to produce a very important anti-inflammatory and anti-tumor factor, butyrate, which plays a key protective role in inflammation<sup>44-46</sup>. The reduced abundance of the bacteria has negative correlation with the pro-inflammatory molecules in our specimens, which indicated its increased sensitivity to inflammatory processes. Butyrate regulates the beneficial bacteria of human intestinal microecological balance, which have important anti-inflammatory and anti-tumor effects. This is consistent with recent evidence demonstrating that increased rectal abundance of *Eubacterium* is associated with less inflammation. The increased *Eubacterium* also foreshows that the response to anti-TNF- $\alpha$  treatment in pa-

tients with inflammatory bowel diseases is positive. The content of *Subdoligranulum* in Group AGE3 is remarkably higher than in Group AGE1 and Group AGE 2. Some researches revealed that *Subdoligranulum* relates to poor metabolic control and chronic inflammation. The changes of its abundance may lead to the disorder of the host metabolism. *Escherichia-shigella* is a conditional pathogen and is associated with a pro-inflammatory state<sup>47</sup>. The abundance of proinflammatory *Escherichia/shigella* was higher in the stools of subjects with cognitive impairment and cerebral amyloidosis. The high abundance of *Escherichia-shigella* shows that young people aged 20-40 are susceptible to digestive diseases such as diarrhea.

## Conclusions

In summary, with the increase of age, the abundance of intestinal flora of healthy adults over 40 years of age decreases, and the diversity and the degree of specimens' dispersion are significantly different from those of 20-40 years old. The decrease in the ratio of *Firmicutes* and *Actinobacteria* indicates that glucose tolerance may decrease with age; the beneficial bacteria *Bifidobacterium* and *Eubacterium* are significantly lower than those of 20-40 years old, and the decrease in *Bifidobacterium* may increase the incidence. There is a risk of cognitive impairment and a reduction in *Eubacterium* may reduce the body's anti-inflammatory and anti-tumor effects. *Subdoligranulum* is associated with poor metabolic control and chronic inflammation, and it is significantly increased compared with young people aged 20-40. Buford<sup>48</sup> shows that the gut microbiome may represent a new type of intervention site for the prevention and/or treatment of a disease. Therefore, effective intervention against the intestinal flora can play a role in delaying aging and preventing diseases.

## Conflict of Interest

The Authors declare that they have no conflict of interests.

## Funding Acknowledgments

Research and Innovation Team of the Prevention and Health Care Center of the Shandong University of Traditional Chinese Medicine.

## References

- 1) BRUZZESE E, CALLEGARI ML, RAIÀ V, VISCOVO S, SCOTTO R, FERRARI S, MORELLI L, BUCCIGROSSI V, LO VA, RUBERTO E, GUARINO A. Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with *Lactobacillus* GG: a randomised clinical trial. *PLoS One* 2014; 9: e87796.
- 2) FRANK DN, ST AA, FELDMAN RA, BOEDEKER EC, HARPAZ N, PACE NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proc Natl Acad Sci U S A* 2007; 104: 13780-13785.
- 3) DUBINSKY MC, LIN YC, DUTRIDGE D, PICORNELL Y, LANDERS CJ, FARRIOR S, WROBEL I, QUIROS A, VASILIAUSKAS EA, GRILL B, ISRAEL D, BAHAR R, CHRISTIE D, WAHBEH G, SILBER G, DALLAZADEH S, SHAH P, THOMAS D, KELTS D, HERSHBERG RM, ELSON CO, TARGAN SR, TAYLOR KD, ROTTER JI, YANG H. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. *Am J Gastroenterol* 2006; 101: 360-367.
- 4) O'KEEFE SJ, OU J, AUFREITER S, O'CONNOR D, SHARMA S, SEPULVEDA J, FUKUWATARI T, SHIBATA K, MAWHINNEY T. Products of the colonic microbiota mediate the effects of diet on colon cancer risk. *J Nutr* 2009; 139: 2044-2048.
- 5) SAMPSON TR, DEBELIUS JW, THRON T, JANSSEN S, SHASTRI GG, ILHAN ZE, CHALLIS C, SCHRETTER CE, ROCHA S, GRADINARU V, CHESSELET MF, KESHAVARZIAN A, SHANNON KM, KRAJMALNIK-BROWN R, WITTUNG-STAFSHED P, KNIGHT R, MAZMANIAN SK. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. *Cell* 2016; 167: 1469-1480.
- 6) HU X, WANG T, JIN F. Alzheimer's disease and gut microbiota. *Sci China Life Sci* 2016; 59: 1006-1023.
- 7) BERER K, MUES M, KOUTROLOS M, RASBI ZA, BOZIKI M, JOHNER C, WEKERLE H, KRISHNAMOORTHY G. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. *Nature* 2011; 479: 538-541.
- 8) BARLOW GM, YU A, MATHUR R. Role of the gut microbiome in obesity and diabetes mellitus. *Nutr Clin Pract* 2015; 30: 787-797.
- 9) KOMAROFF AL. The microbiome and risk for obesity and diabetes. *JAMA* 2017; 317: 355-356.
- 10) JACKSON MA, JEFFERY IB, BEAUMONT M, BELL JT, CLARK AG, LEY RE, O'TOOLE PW, SPECTOR TD, STEVES CJ. Signatures of early frailty in the gut microbiota. *Genome Med* 2016; 8: 8.
- 11) BRITTON RA, IRWIN R, QUACH D, SCHAEFER L, ZHANG J, LEE T, PARAMESWARAN N, MCCABE LR. Probiotic *L. reuteri* treatment prevents bone loss in a menopausal ovariectomized mouse model. *J Cell Physiol* 2014; 229: 1822-1830.
- 12) SCHER JU, SCZESNAK A, LONGMAN RS, SEGATA N, UBEDA C, BIELSKI C, ROSTRON T, CERUNDOLO V, PAMER EG, ABRAMSON SB, HUTTENHOWER C, LITTMAN DR. Expansion of intestinal *Prevotella copri* correlates with enhanced susceptibility to arthritis. *eLife* 2013; 2: e1202.
- 13) VIEIRA AT, MACIA L, GALVAO I, MARTINS FS, CANESSO MC, AMARAL FA, GARCIA CC, MASLOWSKI KM, DE LEON E, SHIM D, NICOLI JR, HARPER JL, TEIXEIRA MM, MACKAY CR. A role for gut microbiota and the metabolite-sensing receptor gpr43 in a murine model of gout. *Arthritis Rheumatol* 2015; 67: 1646-1656.
- 14) BORRE YE, O'KEEFFE GW, CLARKE G, STANTON C, DINAN TG, CRYAN JF. Microbiota and neurodevelopmental windows: implications for brain disorders. *Trends Mol Med* 2014; 20: 509-518.
- 15) FRIEDLAND RP. Mechanisms of molecular mimicry involving the microbiota in neurodegeneration. *J Alzheimers Dis* 2015; 45: 349-362.
- 16) YATSUNENKO T, REY FE, MANARY MJ, TREHAN I, DOMINGUEZ-BELLO MG, CONTRERAS M, MAGRIS M, HIDALGO G, BALDASSANO RN, ANOKHIN AP, HEATH AC, WARNER B, REEDER J, KUCZYNSKI J, CAPORASO JG, LOZUPONE CA, LAUBER C, CLEMENTE JC, KNIGHTS D, KNIGHT R, GORDON JI. Human gut microbiome viewed across age and geography. *Nature* 2012; 486: 222-227.
- 17) MUELLER S, SAUNIER K, HANISCH C, NORIN E, ALM L, MIDTVEDT T, CRESCI A, SILVI S, ORPIANESI C, VERDENELLI MC, CLAVEL T, KOEBNICK C, ZUNFT HJ, DORE J, BLAUT M. Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study. *Appl Environ Microbiol* 2006; 72: 1027-1033.
- 18) BIAGI E, NYLUND L, CANDELA M, OSTAN R, BUCCI L, PINI E, NIKKILA J, MONTI D, SATOKARI R, FRANCESCHI C, BRIGIDI P, DE VOS W. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. *PLoS One* 2010; 5: e10667.
- 19) CLAESSION MJ, CUSACK S, O'SULLIVAN O, GREENE-DINIZ R, DE WEERD H, FLANNERY E, MARCHESI JR, FALUSH D, DINAN T, FITZGERALD G, STANTON C, VAN SINDEREN D, O'CONNOR M, HARNEDY N, O'CONNOR K, HENRY C, O'MAHONY D, FITZGERALD AP, SHANAHAN F, TWOMEY C, HILL C, ROSS RP, O'TOOLE PW. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. *Proc Natl Acad Sci U S A* 2011; 108 Suppl 1: 4586-4591.
- 20) CLAESSION MJ, JEFFERY IB, CONDE S, POWER SE, O'CONNOR EM, CUSACK S, HARRIS HM, COAKLEY M, LAKSHMINARAYANAN B, O'SULLIVAN O, FITZGERALD GF, DEANE J, O'CONNOR M, HARNEDY N, O'CONNOR K, O'MAHONY D, VAN SINDEREN D, WALLACE M, BRENNAN L, STANTON C, MARCHESI JR, FITZGERALD AP, SHANAHAN F, HILL C, ROSS RP, O'TOOLE PW. Gut microbiota composition correlates with diet and health in the elderly. *Nature* 2012; 488: 178-184.
- 21) HOPKINS MJ, MACFARLANE GT. Changes in predominant bacterial populations in human faeces with age and with *Clostridium difficile* infection. *J Med Microbiol* 2002; 51: 448-454.
- 22) WOODMANSEY EJ, MCMURDO ME, MACFARLANE GT, MACFARLANE S. Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and non-antibiotic-treated elderly subjects. *Appl Environ Microbiol* 2004; 70: 6113-6122.

- 23) SACERDOTE C, RICCIERI F. Epidemiological dimensions of the association between type 2 diabetes and cancer: A review of observational studies. *Diabetes Res Clin Pract* 2018; 143: 369-377.
- 24) EZE IC, BASSA FK, ESSE C, KONE S, ACKA F, LAUBHOUET-KOFFI V, KOUASSI D, UTZINGER J, BONFOH B, N'GORAN EK, PROBST-HENSCH N. Epidemiological links between malaria parasitaemia and hypertension: findings from a population-based survey in rural Cote d'Ivoire. *J Hypertens* 2019; 37: 1384-1392.
- 25) GAO AB, XIAO Q, LI LY, GAO Y, ZHANG HN, MIAO J. [Epidemiological survey of the association between non alcoholic fatty liver disease and metabolic syndrome in civil servants of Chongqing city]. *Zhonghua Yu Fang Yi Xue Za Zhi* 2008; 42: 107-110.
- 26) TURNBAUGH PJ, LEY RE, MAHOWALD MA, MAGRINI V, MARDIS ER, GORDON JI. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature* 2006; 444: 1027-1031.
- 27) JACOBS DM, GAUDIER E, VAN DUYNHOVEN J, VAUGHAN EE. Non-digestible food ingredients, colonic microbiota and the impact on gut health and immunity: a role for metabolomics. *Curr Drug Metab* 2009; 10: 41-54.
- 28) ENDT K, STECHER B, CHAFFRON S, SLACK E, TCHITCHEK N, BENECKE A, VAN MAELE L, SIRARD JC, MUELLER AJ, HEIKENWALDER M, MACPHERSON AJ, STRUGNELL R, VON MERING C, HARDT WD. The microbiota mediates pathogen clearance from the gut lumen after non-typhoidal *Salmonella* diarrhea. *PLoS Pathog* 2010; 6: e1001097.
- 29) COLLINS SM, SURETTE M, BERCIK P. The interplay between the intestinal microbiota and the brain. *Nat Rev Microbiol* 2012; 10: 735-742.
- 30) IVANOV II, HONDA K. Intestinal commensal microbes as immune modulators. *Cell Host Microbe* 2012; 12: 496-508.
- 31) DE PRETER V, GEBOS K, VERBRUGGHE K, DE VUYST L, VANHOUTTE T, HUYS G, SWINGS J, POT B, VERBEKE K. The in vivo use of the stable isotope-labelled biomarkers lactose-[15N]ureide and [2H4]tyrosine to assess the effects of pro- and prebiotics on the intestinal flora of healthy human volunteers. *Br J Nutr* 2004; 92: 439-446.
- 32) TOIVANEN P, EEROLA E. A vegan diet changes the intestinal flora. *Rheumatology (Oxford)* 2002; 41: 950-951.
- 33) MUELLER S, SAUNIER K, HANISCH C, NORIN E, ALM L, MIDTVEDT T, CRESCI A, SILVI S, ORPIANESI C, VERDENELLI MC, CLAVEL T, KOEBNICK C, ZUNFT HJ, DORE J, BLAUT M. Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study. *Appl Environ Microbiol* 2006; 72: 1027-1033.
- 34) WEN Z, HE M, PENG C, RAO Y, LI J, LI Z, DU L, LI Y, ZHOU M, HUI O, FENG Y, YANG S. Metabolomics and 16S rRNA gene sequencing analyses of changes in the intestinal flora and biomarkers induced by gastrodia-uncaria treatment in a rat model of chronic migraine. *Front Pharmacol* 2019; 10: 1425.
- 35) ARUMUGAM M, RAES J, PELLETIER E, LE PASLIER D, YAMADA T, MENDE DR, FERNANDES GR, TAP J, BRULS T, BATO JM, BERTALAN M, BORRUEL N, CASELLAS F, FERNANDEZ L, GAUTIER L, HANSEN T, HATTORI M, HAYASHI T, KLEEREBEZEM M, KUROKAWA K, LECLERC M, LEVENEZ F, MANICHANH C, NIELSEN HB, NIELSEN T, PONS N, POULAIN J, QIN J, SICHERITZ-PONTEN T, TIMS S, TORRENTS D, UGARTE E, ZOETENDAL EG, WANG J, GUARNER F, PEDERSEN O, DE VOS WM, BRUNAK S, DORE J, ANTOLIN M, ARTIGUENAVE F, BLOTTIERE HM, ALMEIDA M, BRECHOT C, CARA C, CHERVAUX C, CULTRONE A, DELORME C, DENARIAZ G, DERYN R, FOERSTNER KU, FRISS C, VAN DE GUCHTE M, GUEDON E, HAIMET F, HUBER W, VAN HYLCKAMA-VLIEG J, JAMET A, JUSTE C, KACI G, KNOL J, LAKHDARI O, LAYEC S, LE ROUX K, MAGUIN E, MERIEUX A, MELO MR, M'RINI C, MULLER J, OOZEER R, PARKHILL J, RENAULT P, RESCIGNO M, SANCHEZ N, SUNAGAWA S, TORREJON A, TURNER K, VANDEMEULEBROUCK G, VARELA E, WINOGRADSKY Y, ZELLER G, WEISSENBACH J, EHRlich SD, BORK P. Enterotypes of the human gut microbiome. *Nature* 2011; 473: 174-180.
- 36) MUELLER S, SAUNIER K, HANISCH C, NORIN E, ALM L, MIDTVEDT T, CRESCI A, SILVI S, ORPIANESI C, VERDENELLI MC, CLAVEL T, KOEBNICK C, ZUNFT HJ, DORE J, BLAUT M. Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study. *Appl Environ Microbiol* 2006; 72: 1027-1033.
- 37) BIAGI E, NYLUND L, CANDELA M, OSTAN R, BUCCI L, PINI E, NIKKILA J, MONTI D, SATOKARI R, FRANCESCHI C, BRIGIDI P, DE VOS W. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. *PLoS One* 2010; 5: e10667.
- 38) RABOT S, MEMBREZ M, BLANCHER F, BERGER B, MOINE D, KRAUSE L, BIBILONI R, BRUNEAU A, GERARD P, SIDDHARTH J, LAUBER CL, CHOU CJ. High fat diet drives obesity regardless the composition of gut microbiota in mice. *Sci Rep* 2016; 6: 32484.
- 39) HAYASHI H, SAKAMOTO M, KITAHARA M, BENNO Y. Molecular analysis of fecal microbiota in elderly individuals using 16S rDNA library and T-RFLP. *Microbiol Immunol* 2003; 47: 557-570.
- 40) MATSUMOTO M, BENNO Y. Anti-inflammatory metabolite production in the gut from the consumption of probiotic yogurt containing *Bifidobacterium animalis* subsp. *lactis* LKM512. *Biosci Biotechnol Biochem* 2006; 70: 1287-1292.
- 41) MAKIVUOKKO H, TIHONEN K, TYNKKYNNEN S, PAULIN L, RAUTONEN N. The effect of age and non-steroidal anti-inflammatory drugs on human intestinal microbiota composition. *Br J Nutr* 2010; 103: 227-234.
- 42) BIAGI E, NYLUND L, CANDELA M, OSTAN R, BUCCI L, PINI E, NIKKILA J, MONTI D, SATOKARI R, FRANCESCHI C, BRIGIDI P, DE VOS W. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. *PLoS One* 2010; 5: e10667.
- 43) DECOURT B, LAHIRI DK, SABBAGH MN. Targeting tumor necrosis factor alpha for Alzheimer's disease. *Curr Alzheimer Res* 2017; 14: 412-425.
- 44) PRYDE SE, DUNCAN SH, HOLD GL, STEWART CS, FLINT HJ. The microbiology of butyrate formation in the

- human colon. *FEMS Microbiol Lett* 2002; 217: 133-139.
- 45) KOLHO KL, KORPELA K, JAAKKOLA T, PICHAI MV, ZOETENDAL EG, SALONEN A, DE VOS WM. Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation. *Am J Gastroenterol* 2015; 110: 921-930.
- 46) CHUMPITAZI BP, HOLLISTER EB, OEZGUEN N, TSAI CM, McMEANS AR, LUNA RA, SAVIDGE TC, VERSALOVIC J, SHULMAN RJ. Gut microbiota influences low fermentable substrate diet efficacy in children with irritable bowel syndrome. *Gut Microbes* 2014; 5: 165-175.
- 47) CATTANEO A, CATTANE N, GALLUZZI S, PROVASI S, LOPIZZO N, FESTARI C, FERRARI C, GUERRA UP, PAGHERA B, MUSCIO C, BIANCHETTI A, VOLTA GD, TURLA M, COTELLI MS, GENNUSO M, PELLE A, ZANETTI O, LUSSIGNOLI G, MIRABILE D, BELLANDI D, GENTILE S, BELOTTI G, VILLANI D, HARACH T, BOLMONT T, PADOVANI A, BOCCARDI M, FRISONI GB. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. *Neurobiol Aging* 2017; 49: 60-68.
- 48) BUFORD TW. (Dis)trust your gut: the gut microbiome in age-related inflammation, health, and disease. *Microbiome* 2017; 5: 80.